Petros Pharmaceuticals, Inc.
PTPI
$0.028
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.14% | -20.67% | -12.20% | -42.41% | 6.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.14% | -20.67% | -12.20% | -42.41% | 6.96% |
| Cost of Revenue | -2.61% | -48.93% | -66.17% | -81.09% | -74.62% |
| Gross Profit | 135.28% | -21.31% | -58.25% | -83.44% | -54.08% |
| SG&A Expenses | -9.35% | -24.04% | -28.70% | -13.68% | -18.38% |
| Depreciation & Amortization | -14.35% | -43.18% | -57.49% | -54.60% | -60.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.49% | -35.51% | -44.28% | -31.93% | -37.83% |
| Operating Income | 25.36% | 37.07% | 35.53% | -4.13% | 30.12% |
| Income Before Tax | -325.36% | -92.48% | -31.41% | 91.07% | 84.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -325.36% | -92.48% | -31.41% | 91.06% | 84.24% |
| Earnings from Discontinued Operations | 278.56% | 17.24% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.93% | -61.24% | -75.41% | 62.79% | 67.90% |
| EBIT | 25.36% | 37.07% | 35.53% | -4.13% | 30.12% |
| EBITDA | 33.09% | 47.66% | 45.08% | -12.83% | 31.92% |
| EPS Basic | 68.92% | 68.10% | 42.21% | 37.69% | 38.38% |
| Normalized Basic EPS | 52.43% | 73.23% | 81.50% | 100.67% | 73.06% |
| EPS Diluted | 68.92% | 68.10% | 42.21% | 37.69% | 38.38% |
| Normalized Diluted EPS | 52.43% | 73.23% | 81.50% | 100.67% | 73.06% |
| Average Basic Shares Outstanding | 4,088.34% | 395.67% | 268.66% | 189.91% | 99.37% |
| Average Diluted Shares Outstanding | 4,088.34% | 395.67% | 268.66% | 189.91% | 99.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |